Further research efforts aimed at elucidating the underlying molecular mechanisms and identifying additional genetic and epigenetic alterations that interact with CEBPA mutations are necessary to harness the full potential of CEBPA bZIPInDel mutations in improving the management and prognosis of these AML patients. The gene discussed is CEBPA; the disease is acute myeloid leukemia.